Qube Research & Technologies (QRT)
SABS icon

Qube Research & Technologies (QRT)’s SAB Biotherapeutics SABS Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$92.3K Sell
24,098
-7,049
-23% -$28.1K ﹤0.01% 3076
2025
Q4 		$116K Buy
+31,147
New +$102K ﹤0.01% 3168
2024
Q3 		– Sell
-6
Closed -$19 – 3995
2024
Q2 		$19 Hold
6
– – ﹤0.01% 3582
2024
Q1 		$27 Sell
6
-1
-14% -$6 ﹤0.01% 4253
2023
Q4 		$47 Hold
7
– – ﹤0.01% 4074
2023
Q3 		$43 Buy
+7
New +$51 ﹤0.01% 3828
2022
Q2 		– Sell
-2,418
Closed -$91K – 3051
2022
Q1 		$91K Buy
2,418
+736
+44% +$34K ﹤0.01% 2089
2021
Q4 		$131K Buy
+1,682
New +$158K ﹤0.01% 2079

Other funds holding SABS

VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Qube Research & Technologies (QRT)'s SABS Position: Q1 2026 in Review

Qube Research & Technologies (QRT) reduced its SAB Biotherapeutics (SABS) stake by 23% in Q1 2026, selling an estimated $28.1K and leaving 24,098 shares worth $92.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3076.

Qube Research & Technologies (QRT) first reported a position in SABS in Q4 2021 and has held it in 8 quarters since. The position peaked at $131K in Q4 2021. 76 funds tracked by Wall St. Rank hold SABS as of Q1 2026.

  • Qube Research & Technologies (QRT) held 24,098 shares of SAB Biotherapeutics worth $92.3K as of Q1 2026.
  • Qube Research & Technologies (QRT) sold 7,049 SAB Biotherapeutics shares in Q1 2026, an estimated $28.1K.
  • SAB Biotherapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #3076 holding.
  • Qube Research & Technologies (QRT) first reported a position in SAB Biotherapeutics in Q4 2021 and has held it in 8 quarters since.
  • Qube Research & Technologies (QRT)'s SAB Biotherapeutics position peaked at $131K in Q4 2021.
  • 76 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.